How to appeal a Blue Cross Blue Shield of Massachusetts prostate cancer denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Blue Cross Blue Shield of Massachusetts-specific note: Non-profit; ~3M members. MA has the most expansive state mandated benefits in the US and strong supplemental parity rules. MA OPP (Office of Patient Protection) provides external review separately from carriers — distinct from federal IRO process for fully-insured plans.

What Blue Cross Blue Shield of Massachusetts's policy requires for prostate cancer

Cited policy: BCBS Lynparza (Olaparib) for HRR-mutated Metastatic Castration-Resistant Prostate Cancer

Adult mCRPC with deleterious or suspected-deleterious germline OR somatic HRR mutation (FDA-approved test). HRR panel per PROfound: BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L. Prior progression on enzalutamide OR abiraterone (monotherapy indication). For PROpel combo (olaparib+abiraterone+prednisone): BRCA-mutated 1L mCRPC. Castrate testosterone <50 ng/dL. Olaparib 300 mg PO BID.

How Blue Cross Blue Shield of Massachusetts denies prostate cancer — and how to counter it

Where Blue Cross Blue Shield of Massachusetts pushes back: 1) Only BRCA1/2 covered; 2) HRR result must be germline only; 3) Insufficient ARSI failure for monotherapy.

Counter-arguments that hold up: PROfound NEJM 2020 Hussain — olaparib HRR-mutated mCRPC post-ARSI rPFS HR 0.34 (Cohort A BRCA/ATM) + 0.49 (overall HRR). FDA May 19, 2020 monotherapy label covers 14-gene HRR panel, NOT BRCA-only. Both germline AND somatic HRR mutations qualify per FDA label and NCCN v1.2025. PROpel NEJM Evid 2022 + Lancet 2023 — olaparib+abiraterone 1L mCRPC rPFS benefit (FDA narrowed combo label May 2023 to BRCA-mutated). NCCN v1.2025 Category 1 for HRR-mutated mCRPC post-ARSI.

What Blue Cross Blue Shield of Massachusetts typically denies for prostate cancer

Across Blue Cross Blue Shield of Massachusetts's commercial and Medicare books, denials cluster around a small number of patterns. For prostate cancer, expect:

• MA-specific mandated benefit disputes (most generous in US)
• Behavioral health parity (MA has tighter parity rules than federal MHPAEA)
• Tiered-network provider disputes
• Specialty drug PA

Treatments most often denied in this category

These are the prostate cancer treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Pluvicto (177Lu-PSMA-617)
• Xofigo (radium-223)
• Xtandi (enzalutamide)
• Erleada (apalutamide)
• Nubeqa (darolutamide)
• Zytiga (abiraterone)

How to submit the appeal to Blue Cross Blue Shield of Massachusetts

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Blue Cross Blue Shield of Massachusetts cited in the denial.
3. File the appeal through Blue Cross Blue Shield of Massachusetts's portal (members: https://home.bluecrossma.com ; providers: https://provider.bluecrossma.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Blue Cross Blue Shield of Massachusetts's prior-authorization criteria by drug: Blue Cross Blue Shield of Massachusetts PA criteria on ApprovalHelp.